Actinic Keratosis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The market is segmented By Therapy Type (Topical Medications (Fluorouracil, Imiquimod, Ingenol Mebutate, Other Medications), Procedures (Photodynamic Therapy, Laser, Other Procedures)), By End User and Geography.

Market Snapshot

actinic keratosis treatment 1
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Actinic Keratosis Treatment Market is expected to register a CAGR of 5.3% during the forecast period. Actinic keratosis is a rough and often bumpy patch or lesion that forms on the skin. This condition sometimes called solar keratosis or senile keratosis which enlarges slowly and usually causes no signs or symptoms other than a patch or small spot on the skin. These patches take years to develop, usually first appearing in people over 40 years of age. Actinic keratosis is more common in older people with pale-colored eyes, fair skin, and red or blonde hair who burn easily and do not tan well. Some actinic keratosis may develop into an invasive form of skin cancer called squamous cell carcinoma (SCC). Progression of squamous cell carcinoma (SCC) may be indicated by growth, discomfort/tenderness, and persistent ulceration or bleeding.

According to a study report by J. Welzel et al., published in British Journal of Dermatology 2019, estimates more than 50% of the light‐skinned population is affected with actinic keratosis during their lifetime. Actinic keratosis is the third most common factor for United States patients to consult a dermatologist. In addition, as per the Skin Cancer Foundation, more than 15,000 Americans die each year from squamous cell carcinoma.

Furthermore, increasing prevalence of actinic keratosis, growing demand for minimally invasive procedures and increasing research and development for development of novel therapies are the key driving factors in actinic keratosis treatment market.

Scope of the Report

As per the scope of the report, Actinic keratosis is a rough, scaly patch on skin that develops from years of exposure to the solar radiation. It is commonly found on the face, lips, ears, back of hands, forearms, scalp or neck. Actinic Keratosis Treatment Market is segmented By Therapy, End User and Geography.

By Therapy
Topical Medications
Fluorouracil
Imiquimod
Ingenol Mebutate
Other Medications
Procedures
Photodynamic Therapy
Laser
Other Procedures
By End User
Hospitals and Oncology Centers
Dermatology Clinics
Other End users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Topical Medications Segment is Expected to Hold a Major Market Share in the Actinic Keratosis Treatment Market

The topical medications segment holds a significant market share in the actinic keratosis treatment market and is anticipated to show a similar trend over the forecast period due to the easy availability of products, high target specificity and have a lower risk of scarring. Some of the US Food and Drug Administration (FDA) approved medications for the treatment of actinic keratoses are topical fluorouracil, imiquimod, diclofenac, ingenol mebutate, and combination treatment with medications. As per study report published in British Medical Journal 2019, in England, the prevalence of actinic keratoses was about 15% in men and 5.9% in women above 40 years of age, this prevalence was elevated to 34.1% and 18.2% for men and women, respectively, in patients older than 70 years. Actinic keratosis is considered precancerous because a cutaneous squamous cell carcinoma may arise from actinic keratosis. As the number of actinic keratosis increases the chance of developing squamous cell carcinoma increases. Furthermore, promising pipeline drugs and high adoption of combination treatment are the key driving factors in the topical medications segment.

Actinic Keratosis Treatment key trend 1.png

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global actinic keratosis treatment market due to growing awareness about the occurrence of actinic keratosis and associated risk of squamous cell carcinoma in this region. According to the American Academy of Dermatology Association, estimates that more than 40 million Americans develop actinic keratoses (AKs) each year. In addition, about 60% of the Americans above 40 years of age, actinic keratosis is predisposed to develop having at least 1 actinic keratosis lesion. Furthermore, the presence of well-established healthcare infrastructure and increasing healthcare spending is also fueling the growth of the overall regional market to a large extent.

Actinic Keratosis 2

Competitive Landscape

The Actinic Keratosis Treatment Market is Consolidated competitive and consists of a few major players. Some of the prominent players operating in the actinic keratosis treatment market are Bausch Health Companies Inc, LEO Pharma A/S, Almirall, S.A., Biofrontera AG, Sun Pharmaceutical Industries Limited, 3M Company, Galderma SA, Alma Lasers, Novartis AG and Hill Dermaceuticals, Inc.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Actinic Keratosis Worldwide

      2. 4.2.2 Growing Demand for Minimally Invasive Procedures

      3. 4.2.3 Favorable Reimbursement Policies

    3. 4.3 Market Restraints

      1. 4.3.1 Risk Factors Associated With Available Treatment Options

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Therapy

      1. 5.1.1 Topical Medications

        1. 5.1.1.1 Fluorouracil

        2. 5.1.1.2 Imiquimod

        3. 5.1.1.3 Ingenol Mebutate

        4. 5.1.1.4 Other Medications

      2. 5.1.2 Procedures

        1. 5.1.2.1 Photodynamic Therapy

        2. 5.1.2.2 Laser

        3. 5.1.2.3 Other Procedures

    2. 5.2 By End User

      1. 5.2.1 Hospitals and Oncology Centers

      2. 5.2.2 Dermatology Clinics

      3. 5.2.3 Other End users

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bausch Health Companies Inc

      2. 6.1.2 LEO Pharma A/S

      3. 6.1.3 Almirall, S.A.

      4. 6.1.4 Biofrontera AG

      5. 6.1.5 Sun Pharmaceutical Industries Limited

      6. 6.1.6 3M Company

      7. 6.1.7 Galderma SA

      8. 6.1.8 Alma Lasers

      9. 6.1.9 Novartis AG

      10. 6.1.10 Hill Dermaceuticals, Inc

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The undefined market is studied from 2018 - 2026.

The undefined is growing at a CAGR of 5.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Bausch Health Companies Inc, LEO Pharma A/S, Almirall, S.A., Biofrontera AG, Sun Pharmaceutical Industries Limited are the major companies operating in undefined.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!